Oxfam International believes the Global Fund should put an end to the Affordable Medicines Facility for malaria program, which subsidizes the cost of artemisinin combination therapy treatments and encourages its sale in the private sector.
In a report released Oct. 24, Oxfam said AMFm is operating at a “risky” cost, increasing the possibility of misdiagnosis and causing excessive orders of ACT treatments.
In a statement to the BBC, the Global Fund dismissed Oxfam’s claims as “simply untrue,” stressing that AMFm has made high-quality malaria medicines available to more people at significantly lower prices.
“Some Western aid groups oppose a pragmatic approach that includes any involvement of the private sector,” it said. “Before the launch of AMFm, life-saving malaria treatments cost up to 20 times as much.”
The Global Fund released the results of an independent evaluation of the program’s pilot phase early this month. The report notes that although some benchmarks were met, the level of success varied among the eight pilot areas. Further, while the program’s impact on the private for-profit sector has been a “game changer,” it had a limited influence on the public sector.
The program, launched in 2009, has been piloted in eight countries and has subsidized more than 300 million ACT treatments. Its pilot phase is set to conclude in December 2012.
Amy Lieberman is a Devex correspondent and freelance journalist based in New York, where she has focused her coverage on the United Nations and global health. Her work has appeared in Women's eNews, IRIN, Policy Innovations, Europa Newswire and The New York Observer, among other publications.